Illness Perception, Emotional Distress, And Obsessive-Compulsive Symptomatology In Patients With Alopecia Areata: A Mediation Study

In this study, researchers developed and tested an Italian version of the Skindex-16AA to assess Health-Related Quality of Life in patients with moderate-to-severe Alopecia Areata, emphasizing the importance of patient perception in evaluating their mental health and quality of life.

This study identifies various nail changes in alopecia areata, which can affect quality of life, and suggests that while spontaneous improvement is possible, further research is needed to refine treatment strategies.

This consensus statement outlines a treatment algorithm for alopecia areata, detailing systemic treatment indications and options, including EMA-approved medications baricitinib and ritlecitinib for severe cases, as well as other off-label treatments and adjuvant therapies like oral minoxidil.

This study, involving an international panel of 16 psychodermatology experts, proposed a new classification system for psychodermatology disorders that aims to unify previous classifications and improve their management by systematizing disorders into two main categories: primary mental health disorders and primary skin disorders.

This observational study found that patients with various skin diseases across 17 European countries experience higher levels of perceived stigmatization than skin-healthy controls, particularly those with psoriasis, atopic dermatitis, alopecia, and bullous disorders, with factors such as disease severity and psychological distress influencing stigmatization levels.

This study found that the emotional impact of alopecia areata is significant, but it may not correlate directly with the extent of hair loss since some individuals adapt to the condition.

This review discusses psychological treatments for alopecia, finding limited but positive effects on mental health, quality of life, and possibly hair growth; however, more research is needed to establish intervention efficacy.

This study found that people with alopecia areata have higher rates of depression and anxiety, leading to increased mental health treatment burden, more time off work, and higher unemployment compared to the general population.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

This review discusses the substantial impact of alopecia areata on patients' health-related quality of life, highlighting issues such as personality changes, emotional and social difficulties, and a common occurrence of alexithymia, and emphasizes the need for more specific assessment tools.

This review discusses immune privilege in anagen hair follicles and its collapse in alopecia areata, emphasizing the importance of restoring this function for effective management and disease relapse prevention.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

This study found that patients with alopecia areata reported worse quality of life and higher anxiety and depression levels compared to those with androgenetic alopecia and healthy controls.

This study found that the severity, duration, and relapse rate of alopecia areata decreased with older age at onset, while relapses mostly occurred early and declined over time.

This study found that alopecia areata is linked with a higher prevalence of systemic and psychiatric diseases, suggesting that physicians should monitor for these potential comorbidities.

Most people with alopecia areata have nail changes, which are common but don't greatly affect their quality of life.

More research is needed to understand alopecia areata severity.

This study found that patients with alopecia areata experience significant impairments in health-related quality of life, notably affecting mental health, according to various quality of life assessment tools.

This review reports that alopecia areata affects about 2% of people globally and is linked with psychiatric and medical comorbidities, highlighting its significant disease burden.

This study identified key genetic regions associated with alopecia areata, highlighting both acquired and innate immune involvement, with a novel link to the upregulation of ULBP ligands in autoimmune disease.